Stay updated with breaking news from S Fda. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Food Standards Australia New Zealand (FSANZ) is investigating contamination allegations involving spice mixes from Indian companies MDH and Everest. Hong Kong and Singapore have already taken action due to high levels of ethylene oxide found in the products. Australian authorities are coordinating with international agencies to determine if a recall is necessary.
(Reuters) -X4 Pharmaceuticals said on Monday the U.S. FDA has approved its therapy to treat a rare genetic immunodeficiency disease in patients 12 years of age and older, sending its shares up 16% before the bell. X4's mavorixafor, which will be sold under the brand name Xolremdi, is the first therapy to get U.S. approval specifically for the treatment of WHIM syndrome. WHIM is characterized by disorders in which the body's immune system does not function properly.
US customs rejected 31% MDH spice powder products over 6 months
The statement from the spice maker came days after Hong Kong and Singapore banned the sale of the two Indian spice brands in their countries - MDH and Everest, claiming that they detected the presence of carcinogenic pesticide ethylene oxide in several spice mixes.
Treatment called has a price tag of $3.5m, same is that of Hemgenix produced by CSL Ltd